This week is Clinical Trials Awareness Week — an annual event to recognize the important role clinical trials play in helping develop safe and effective medicines.
As the biopharmaceutical industry innovates and introduces cutting edge treatments and cures, clinical trials are changing too, which is good news for patients. New approaches to designing clinical trials can not only streamline the drug development process, but can also increase patient involvement in the research and development process, enhance awareness and improve participation.
Active participation from patients in the full spectrum of clinical trial development and design can yield important insights on disease burden and inform the development of novel clinical endpoints. One way researchers are collaborating with patients and patient advocacy groups is the identification of patient-focused study endpoints and design features. Advancements in technology are also enabling new drug development tools such as biosensors, electronic patient diaries and apps to help make participation more convenient, while allowing patients to contribute information directly.
Advances in clinical study design are also impacting the research and development lifecycle and facilitating earlier access to new and potential treatment options for patients. Complex clinical trial designs enable studies to evolve as more information is gathered, creating efficiencies that can streamline drug development time. Similarly, expanded clinical data analysis techniques can help monitor patients’ responses to treatments and make clinical development programs more efficient.
Additionally, new highly targeted treatment approaches such as cell and gene therapies are able to target diseases that previously had few treatment options. Clinical studies with these types of treatments use novel study designs to identify the right patients for treatment and increase the “signal to noise” ratio.
The biopharmaceutical industry is responsible for the vast majority of clinical research, accounting for nearly 90 percent of all spending on clinical trials of medicines and devices. However, we know that we can’t do it alone. We are thankful for the participation of patients in clinical trials and are committed to leveraging innovations to ensure patients involved in clinical research feel represented and supported.
Learn more about current innovative clinical trials here.
Richard Moscicki M D
Dr. Moscicki served as executive vice president, Science and Regulatory Advocacy and chief medical officer at PhRMA from 2017-summer of 2022. He joined the organization after serving as the Deputy Center Director for Science Operations for the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) since 2013. While at FDA, Dr. Moscicki brought executive direction of Center operations and leadership in overseeing the development, implementation, and direction of CDER’s programs. Previous positions include serving as Chief Medical Officer at Genzyme Corporation from 1992 to 2011, where he was responsible for worldwide global regulatory and pharmacovigilance matters, as well as all aspects of clinical research and medical affairs for the company. He served as the senior vice president and head of Clinical Development at Sanofi-Genzyme from 2011-2013.
Richard Moscicki M D
Why PDUFA VIII keeps patients first and strengthens America's biopharma leadership
PDUFA creates an efficient drug review process that benefits American patients
Advancing patient care: A look at new medicines approved in 2025
PDUFA: Essential to America’s edge in drug development and patient access
ICYMI: PhRMA submits comments to White House on artificial intelligence
New research: Industry sponsored clinical trials contribute billions to state economies
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
The use of real-world data in drug development
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
Decentralized clinical trials and the future of drug development
How FDA’s modernization strategy could improve drug development
ICYMI: PhRMA CMO Dr. Michael Ybarra speaks with Dr. Fabian Sandoval about clinical trial diversity
PhRMA submits comments to OSTP on enhancing clinical trial diversity
Novel medicines approved in 2022 offer increased treatment options for patients
PDUFA and BsUFA reauthorizations are wins for patients
Timely reauthorization of PDUFA and BsUFA is vital to the FDA’s review of medicines
Word of the Month: Biomarkers and surrogate endpoints
Ensuring timely reauthorization of PDUFA and BsUFA
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
The importance of timely PDUFA and BsUFA reauthorization
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
World AIDS Day: Remembering those we’ve lost and exploring the continued fight against HIV/AIDS
Meeting Tomorrow: Looking ahead to PDUFA VII
PDUFA VII is critical for future biopharmaceutical innovation and for patients
3 things that support robust biopharmaceutical research and development
Watch: Building trust and enhancing clinical trial diversity
PhRMA hosts first stakeholder workshop on clinical trial diversity
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Increasing diversity at investigator sites could increase minority participation in clinical trials
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Report: More than 1,300 medicines and vaccines in development to help fight cancer
Committing to diversity, equity and inclusion: A call to action for clinical trials
Just released: PhRMA members’ new clinical trial diversity principles
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
New report explores setbacks that bring future cancer success stories
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
What scientific experts are saying about vaccine safety
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
Guest Post: Preserving clinical research sites during the coronavirus pandemic
New report shows nearly 260 vaccines in development, including dozens for COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
COVID-19 Response: Supporting the frontline
America’s biopharmaceutical companies are working around the clock to beat coronavirus
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Nearly 140 medicines in development to treat mental illness
New report finds 15 new oncology therapies launched last year
Clinical trials impact state economies
Event: New era of medicine comes to Capitol Hill
New report shows more than 160 medicines in development for diabetes and related conditions
Minority health matters
New report shows nearly 20 innovative medicines in development for sickle cell disease
Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
Putting 2018 medicine approvals in context
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
Examining the truth behind clinical trial costs
New report details the setbacks and challenges to Alzheimer’s research
Disrupting Alzheimer's
Aspen Spotlight Health: Discussing the forefront of innovation
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Guest post: Ensuring communities have a seat at the table: The importance of diversity in clinical trials
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
Bringing innovation to clinical trial design
Rare Disease Day: Unmet need inspires innovation
ICYMI: Why 2017 medicine approvals matter
EFPIA-PhRMA Principles successfully enable responsible clinical trial data sharing
Guest Post: Film chronicles clinical trials ‘paying it forward’
New report and event examine the new era of vaccines
A new era in cancer
The next five years of PDUFA VI: Driving the availability of innovative treatments for patients
How biopharmaceutical collaboration is driving a new era of medicine
Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation
Biopharmaceutical industry policies aim to increase access to clinical trial data
Finding cures for incurable diseases
New report portrays flourishing pipeline
Why reauthorization of PDUFA matters
Going boldly together: New advancements and new anniversaries
Examining the brain in The New Era of Medicine
A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements
Guest Post: The Clinical trial experience from a patient & researcher perspective
Guest Post: Patients as research partners - Rethinking patient access to clinical trial data
Guest Post: Spotlighting the heroes in clinical trials
Guest Post: Advancing oncology research through clinical trials
Clinical Trials Awareness Week: Celebrating the impact of clinical research
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
A new era in genomics
Driving innovation through collaboration
Guest Post: The importance of a modern FDA in drug discovery
ICYMI: New era of medicine initiative kicks off in Boston
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
Watch: Biomarkers in drug development with Dr. Bernie Zeiher
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY
The 20-year journey yielding a new weapon against cancer
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Clinical Trials
PDUFA
New Era of Medicine
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Clinical Trials Awareness Week: Celebrating innovation in clinical research